Trial Profile

A Phase 1, Randomized, Placebo-Controlled, First-in-Human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered KT-579 in Healthy Adult Participants

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KT 579 (Primary)
Indications Dermatomyositis; Inflammatory bowel diseases; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus; Systemic scleroderma
Focus Adverse reactions; First in man
Sponsors Kymera Therapeutics

14 Jan 2026 According to a Kymera Therapeutics media release, KT-579 Phase 1 HV clinical trial expected to start in 1Q26, with data expected in 2H26
08 Jun 2025 New trial record
09 May 2025 According to a Kymera Therapeutics media release, IND-enabling studies for KT-579 are ongoing, with Phase 1 testing expected to begin in early 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com